Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial

BACKGROUND: Fluticasone furoate/vilanterol (FF/VI) is a novel once-daily (OD) inhaled corticosteroid/long-acting β(2) agonist combination in development for chronic obstructive pulmonary disease (COPD) and asthma. TRIAL DESIGN: A multicentre, randomised, double-blind, parallel-group, placebo-control...

Descripción completa

Detalles Bibliográficos
Autores principales: Lötvall, J, Bakke, P S, Bjermer, L, Steinshamn, S, Scott-Wilson, C, Crim, C, Sanford, L, Haumann, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Respiratory Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263438/
https://www.ncbi.nlm.nih.gov/pubmed/22267687
http://dx.doi.org/10.1136/bmjopen-2011-000370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263438/
https://www.ncbi.nlm.nih.gov/pubmed/22267687
http://dx.doi.org/10.1136/bmjopen-2011-000370

Ejemplares similares